Costly leukemia pill wins UK green light after price cut
Costly blood cancer pill sold in Europe by Johnson & Johnson will be made routinely available to certain patients in Britain with chronic lymphocytic leukemia, after the U.S. company agreed to cut the price.

The National Institute for Health and Care Excellence (NICE) said on Friday the discount offered by J&J meant it could now recommend Imbruvica as offering value for money to the state-run health service...